Cyclin Dependent Kinase Inhibitor 2D (CDKN2D) Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-Cyclin Dependent Kinase Inhibitor 2D (CDKN2D) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | Cyclin Dependent Kinase Inhibitor 2D (CDKN2D) |
| Clone | polyclonal |
| Host Species | Rabbit |
| Reactive Species | human |
| Isotype | n/a |
| Format | affinity purified |
| Size | 0.01 mg, 0.02 mg, 0.05 mg |
| Concentration | 200ug/ml |
| Applications | Western Blot (WB), Immunocytochemistry (ICC), Immunohistochemistry (IHC) Formalin/Paraffin, ELISA (EIA) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | The antibody is a rabbit polyclonal antibody raised against CDKN2D. It has been selected for its ability to recognize CDKN2D in immunohistochemical staining and western blotting. |
| Immunogen | Immunoglobulin Type: IgG Quality Control: Content: The quality control contains recombinant CDKN2D (Met1~Leu166) disposed in loading buffer. Usage: 10uL per well when 3,3'-Diaminobenzidine(DAB) as the substrate. 5uL per well when used in enhanced chemilumescent (ECL). Note: The quality control is specifically manufactured as the positive control. Not used for other purposes. Loading Buffer: 100mM Tris(pH8.8), 2% SDS, 200mM NaCl, 50% glycerol,BPB 0.01%, NaN3 0.02%. Conjugated Antibody: The APC co |
| Other Names | [INK4D; p19; p19-INK4D; Cyclin-dependent kinase 4 inhibitor D] |
| Gene, Accession # | [CDKN2D], Gene ID: 1032, NCBI: NP_001791.1, UniProt: P55273 |
| Catalog # | MBS2033836 |
| Price | $110, $130, $175 |
| Order / More Info | Cyclin Dependent Kinase Inhibitor 2D (CDKN2D) Antibody from MYBIOSOURCE INC. |
| Product Specific References | n/a |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies